# To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

> **NCT02162771** · PHASE3 · COMPLETED · sponsor: **Celltrion** · enrollment: 140 (actual)

## Conditions studied

- Lymphoma, Follicular

## Interventions

- **BIOLOGICAL:** Rituxan
- **BIOLOGICAL:** CT-P10
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02162771
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-14
- **Primary completion:** 2016-01-12
- **Final completion:** 2018-12-29
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2020-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02162771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02162771, "To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02162771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*